SEC Company Response from Protalix BioTherapeutics, Inc. (PLX) (CIK 0001006281) (PLX) — Apr 27, 2022
Protalix BioTherapeutics, Inc. (PLX) (CIK 0001006281)
Date: April 27, 2022 · CIK: 0001006281 · Accession: 0001104659-22-050904
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-264394
Letter
VIA EDGAR Office of Life Sciences Division of Corporation Finance Re: Protalix BioTherapeutics, Inc. Registration Statement on Form S-3 Filed April 20, 2022 File No. 333-264394
Dear Ms. Ansart:
We refer to the registration statement on Form S-3 (File No. 333-264394) (the “Registration Statement”) of Protalix BioTherapeutics, Inc., a Delaware corporation (the “Company”). In accordance with Rule 461 under the Securities Act of 1933, as amended, the Company hereby respectfully requests the acceleration of the effectiveness of the Registration Statement so that it may become effective at 5:00 p.m. (Eastern time) on April 29, 2022 or as soon as practicable thereafter, which shall be after we file our Definitive Proxy Statement for our Annual Meeting of Stockholders scheduled for June 30, 2022.
We thank you in advance for your time and attention to the Registration Statement. Should you wish to discuss the enclosed materials at any time, please do not hesitate to contact me at +972 (4) 902-8100 or Eyal.Rubin@protalix.com, or the Company’s counsel, Brian Hirshberg of Mayer Brown LLP at +1 (212) 506-2176 or bhirshberg@mayerbrown.com.
Sincerely,
/s/ Eyal Rubin
Show Raw Text
CORRESP
1
filename1.htm
April 27, 2022
VIA EDGAR
Jessica Ansart
Office of Life Sciences
U.S. Securities and Exchange Commission
Division of Corporation Finance
Mail Stop 4720
100 F Street, N.E.
Washington, D.C. 20549
Re: Protalix BioTherapeutics, Inc.
Registration Statement on Form S-3
Filed April 20, 2022
File No. 333-264394
Dear Ms. Ansart:
We refer to the registration statement on Form
S-3 (File No. 333-264394) (the “Registration Statement”) of Protalix BioTherapeutics, Inc., a Delaware corporation (the “Company”).
In accordance with Rule 461 under the Securities Act of 1933, as amended, the Company hereby respectfully requests the acceleration of
the effectiveness of the Registration Statement so that it may become effective at 5:00 p.m. (Eastern time) on April 29, 2022 or
as soon as practicable thereafter, which shall be after we file our Definitive Proxy Statement for our Annual Meeting of Stockholders
scheduled for June 30, 2022.
We thank you in advance for your time and attention
to the Registration Statement. Should you wish to discuss the enclosed materials at any time, please do not hesitate to contact me at
+972 (4) 902-8100 or Eyal.Rubin@protalix.com, or the Company’s counsel, Brian Hirshberg of Mayer Brown LLP at +1 (212) 506-2176
or bhirshberg@mayerbrown.com.
Sincerely,
/s/ Eyal Rubin
Eyal Rubin
Sr. Vice President and Chief Financial Officer
Protalix BioTherapeutics, Inc.
cc: Dror Bashan
Protalix BioTherapeutics, Inc.
Brian
Hirshberg
Mayer Brown LLP
2
Snunit Street, Science Park P.O.B. 455, Carmiel 20100, Israel
Tel:
972-4-988-9488 | Fax: 972-4-988-9489 | Web: www.protalix.com